[36A11-36A11];[36B3-36B3];
A set of ~800 largely isogenic deficiency stocks created by FLP-induced recombination between FRT-carrying transgenic insertions; molecularly defined deletion endpoints correspond to initial location of the progenitor insertions. Designed to fill gaps in deletion coverage and breakpoint placement; also used to replace older available deficiencies that have not been molecularly mapped.
36A11;36B3
Breakpoint from FlyBase's release 5 sequence location of progenitor insertion.
Inferred to overlap with: Df(2L)Exel6039.
The presence of P+PBac{XP5.WH5}BSC325 was verified using the PCR methods and primers described in FBrf0175003.
Exelixis, Inc. determined the insertion site of P{XP}d03995 to be at Release 3 genomic coordinate 16694253 on chromosome arm 2L. The Gene Disruption project determined the insertion site of P{XP}d03995 to be at Release 3 genomic coordinate 16694619 on arm 2L. This corresponds to 36A11 on both the Release 3 and 5 genome maps. The predicted position of PBac{WH}CG15133f05507 on the Release 5 map is 36B3. Consequently, the cytological breakpoints of Df(2L)BSC325 are predicted to be 36A11;36B3.